ArticleCase reports in pulmonology2025
Usefulness of Telemonitoring in Respiratory Deterioration in a Patient Treated With Home High-Flow Nasal Therapy.
Article in Case reports in pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 63-year-old male with overlap syndrome had high-flow nasal cannula (HFNC) therapy added to his treatment in May 2023 after reporting reduced exercise tolerance due to dyspnea and recurrence of chronic bronchial congestion on existing therapy (noninvasive ventilation and appropriate drug treatment). HFNC therapy (Lumis HFT; ResMed) was started with prescribed usage of 2 h/day, a flow of 20 L/min, and a temperature of 37°C. Within 15 days, the patient noted improved clearance with thinner secretions, and then secretion volume decreased after 2 months. Six months after having HFNC connected to a telemonitoring platform (AirView), the homecare technician observed a sudden increase in HFNC usage (to > 4 h/day). After being contacted by the technician, the patient reported increased sputum production, low-grade fever, and exertional dyspnea. Evaluations found
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.